TY - JOUR
T1 - Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates
AU - Prenafeta, Antoni
AU - Bech-Sàbat, Gregori
AU - Moros, Alexandra
AU - Barreiro, Antonio
AU - Fernández, Alex
AU - Cañete, Manuel
AU - Roca, Mercè
AU - González-González, Luis
AU - Garriga, Carme
AU - Confais, Joachim
AU - Toussenot, Marion
AU - Contamin, Hugues
AU - Pizzorno, Andrés
AU - Rosa-Calatrava, Manuel
AU - Pradenas, Edwards
AU - Marfil, Sílvia
AU - Blanco, Julià
AU - Rica, Paula Cebollada
AU - Sisteré-Oró, Marta
AU - Meyerhans, Andreas
AU - Lorca, Cristina
AU - Segalés Coma, Joaquim
AU - Prat, Teresa
AU - March, Ricard
AU - Ferrer, Laura
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/7/21
Y1 - 2023/7/21
N2 - SARS-CoV-2 emerged in December 2019 and quickly spread worldwide, continuously striking with an unpredictable evolution. Despite the success in vaccine production and mass vaccination programs, the situation is not still completely controlled, and therefore accessible second-generation vaccines are required to mitigate the pandemic. We previously developed an adjuvanted vaccine candidate coded PHH-1V, based on a heterodimer fusion protein comprising the RBD domain of two SARS-CoV-2 variants. Here, we report data on the efficacy, safety, and immunogenicity of PHH-1V in cynomolgus macaques. PHH-1V prime-boost vaccination induces high levels of RBD-specific IgG binding and neutralizing antibodies against several SARS-CoV-2 variants, as well as a balanced Th1/Th2 cellular immune response. Remarkably, PHH-1V vaccination prevents SARS-CoV-2 replication in the lower respiratory tract and significantly reduces viral load in the upper respiratory tract after an experimental infection. These results highlight the potential use of the PHH-1V vaccine in humans, currently undergoing Phase III clinical trials.
AB - SARS-CoV-2 emerged in December 2019 and quickly spread worldwide, continuously striking with an unpredictable evolution. Despite the success in vaccine production and mass vaccination programs, the situation is not still completely controlled, and therefore accessible second-generation vaccines are required to mitigate the pandemic. We previously developed an adjuvanted vaccine candidate coded PHH-1V, based on a heterodimer fusion protein comprising the RBD domain of two SARS-CoV-2 variants. Here, we report data on the efficacy, safety, and immunogenicity of PHH-1V in cynomolgus macaques. PHH-1V prime-boost vaccination induces high levels of RBD-specific IgG binding and neutralizing antibodies against several SARS-CoV-2 variants, as well as a balanced Th1/Th2 cellular immune response. Remarkably, PHH-1V vaccination prevents SARS-CoV-2 replication in the lower respiratory tract and significantly reduces viral load in the upper respiratory tract after an experimental infection. These results highlight the potential use of the PHH-1V vaccine in humans, currently undergoing Phase III clinical trials.
KW - Health sciences
KW - Immunology
KW - Immune response
KW - Microbiology
UR - https://www.scopus.com/pages/publications/85165379052
U2 - 10.1016/j.isci.2023.107224
DO - 10.1016/j.isci.2023.107224
M3 - Article
C2 - 37502366
SN - 2589-0042
VL - 26
SP - 107224
JO - iScience
JF - iScience
IS - 7
M1 - 107224
ER -
